Navigation Links
Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 Diabetes
Date:9/20/2010

ntly higher number of patients achieving A1C levels less than or equal to 6.5 percent with lixisenatide (31.9% two-step, 25.4% one-step) and <7.0 percent (52.2% two-step, 46.5% one-step) versus placebo (p<0.01).

Lixisenatide significantly reduced the mean change from baseline two-hours postprandial glucose by respectively -4.51 and -5.47 mmol/L (p<0.0001) in the one-step and two-step titration groups with mean decreases in body weight observed in all groups. In addition, lixisenatide once-daily reduced glucose excursion respectively by -3.77 and -4.36 mmol/L in the one-step and two-step titration groups with mean decreases in body weight observed in all groups.

Lixisenatide was well tolerated. Only one serious treatment-emergent adverse event (TEAE) occurred in the lixisenatide group (0.4%) versus five in the placebo group (4.1%). Nausea was the most frequent TEAE with lixisenatide (24.2% for lixisenatide 2-step, 20.2% for lixisenatide 1-step, 4.1% for placebo). The rate of symptomatic hypoglycemia was 1.7 percent and 1.6 percent in the lixisenatide and placebo groups, respectively.

About Lixisenatide (AVE 0010)Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus.  Lixisenatide was in-licensed by sanofi-aventis from Zealand Pharma A/S (Copenhagen, Denmark).

The efficacy and safety of lixisenatide once-daily is being assessed in the GetGoal Phase III clinical trial program. The GetGoal clinical trial program started in May 2008 and has enrolled more than 4,500 patients. The enrollment of the eight other studies of the GetGoal Phase III program assessing efficacy and safety of lixisenatide in adult patients with type 2 diabetes mellitus treated with various oral antidiabetic agents or insulin was completed at the end of 2009.

The next results of the GetGoal Phase III program are expected to be released in Q2 2011.

About GLP-
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
2. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
3. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
4. Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting
5. Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be Presented at Major Medical Meeting
6. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
7. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
8. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
9. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
10. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
11. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: ... pharmaceutical company with the largest cardio-cerebral vascular ("CCV") ... prescription drug market, today announced the unaudited consolidated ... the "Group") for the six months ended 30 ... the Six months ended 30 JuneKey Income Statement ...
(Date:8/27/2014)... N.C. , Aug. 27, 2014 Kewaunee ... its Board of Directors increased its quarterly cash dividend ... eleven cents per outstanding share, beginning with the dividend ... at the close of business on September 8, 2014. ... Founded in 1906, Kewaunee Scientific Corporation is a ...
(Date:8/27/2014)... THOUSAND OAKS, Calif. , Aug. 27, 2014 /PRNewswire/ ... the U.S. Food and Drug Administration (FDA) has granted ... chronic heart failure (HF). Ivabradine is an oral drug ... ("funny" current) in the sinoatrial node, the body,s cardiac ... rate without negative effects on myocardial contractility or ventricular ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... 20, 2011 Chembio Diagnostics, Inc. (OTC/QB: CEMI & ... diagnostic tests, announced today that the Company will release ... the open of the market on Thursday, November 3, ... be available immediately after 9:15 a.m. on our web ...
... Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... 30, 2011, on Thursday, October 27, 2011, after the markets close. ... Time to discuss the financial results and provide an update on ... To access the live conference call on October 27, ...
Cached Medicine Technology:Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results 2Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results 3Cardica to Announce Fiscal 2012 First Quarter Financial Results on Thursday, October 27, 2011 2
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According ... Market Research "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, ... Electrical, Ultrasound, Microwave, Cryotherapy) - Global Industry Analysis, ... 2020," the global ablation technologies market was valued ... estimated to reach a market worth USD 10,611 ...
(Date:8/27/2014)... and tested an advanced statistical model to evaluate ... disease as published yesterday in Human Genetics ... gap in current analyses. Complex diseases like cancer ... environmental factors. When many such combinations are studied, ... chance combinations among affected individuals becomes difficult. In ...
(Date:8/27/2014)... August 27, 2014 Nava Beauty Store and ... to all patrons from those seeking luxury care products to ... They carry high end luxurious brands like Valmont and Elemis ... also sells brands like Dermalogica and Bliss to provide easy ... customers. They also offer purely organic skin care products such ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2
... conducted among about 200 people with multiple sclerosis ( ... such as pain, tiredness,// emotional well-being, vitality, social functioning, ... living. Results from the MS patients were then compared ... the general population. ,Multiple sclerosis patients in the ...
... help doctors identify which postmenopausal women are at an ... most important// predictor of bone fracture in postmenopausal women ... mineral density is measured by a T-score. As the ... has been what level of a T-score indicates an ...
... standards for measuring blood pressure in children based on age, ... children as young as age 3 should receive regular blood ... percentile for blood pressure are diagnosed with high blood pressure. ... are said to have pre-hypertension -- a relatively new classification ...
... population carries a gene that puts them at risk for ... offspring.// Researchers say they already know one form of the ... to neural tube defects. They speculated another form of the ... ,Researchers studied about 400 people with neural tube defects, comparing ...
... 1 million cases of skin cancer are diagnosed. More than ... more than 7,000 people die yearly. Now, doctors are using ... some patients. ,Mary Louise Gramkow spent her life in ... sort of thing. [I am] just an outdoor person.” All ...
... worn by medical staff carry disease-causing bacteria. Researchers sampled ... and security personnel at a teaching hospital. Their data ... by the medical staff were contaminated with bacteria. ... transfer disease to patients, it is a good opportunity ...
Cached Medicine News:
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: